BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report.

In the NCI MATCH trial, Subprotocol H, which served as the basis for FDA approval of dabrafenib plus trametinib for tissue-agnostic indications, a high degree of tumor mutational heterogeneity was reported and trends toward differences in patient outcomes were observed, although these did not reach statistical significance ( 52 ).

also in 111,027 other papers